Eight new medicines recommended for approval
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting.
The CHMP recommended granting a marketing authorisation for Altuvoct* (efanesoctocog alfa), for the treatment and prophylaxis of bleeding in patients with haemophilia A, a rare inherited bleeding disorder caused by lack of factor VIII.
The committee adopted a positive opinion for Fruzaqla (fruquintinib), indicated for the treatment of patients with previously treated metastatic colorectal cancer.
The CHMP gave a positive opinion for Jeraygo (aprocitentan), for the treatment of resistant hypertension.
Obgemsa (vibegron) received a positive opinion for the treatment of adults with overactive bladder syndrome.
The CHMP gave a positive opinion for Truqap (capivasertib), for the treatment of locally advanced or metastatic breast cancer with one or more specific mutations…
